FDA-cleared remote monitoring platform collecting wearable digital biomarkers for decentralized clinical trials.

Empatica Inc., an MIT spinoff, provides AI-enabled healthcare tools and FDA-approved wearables for physiological data interpretation and seizure alerting.
Empatica Inc., an MIT Media Lab spinoff founded in Cambridge, Massachusetts, focuses on advancing healthcare through AI-enabled tools. The company’s core mission is to improve forecasting, monitoring, research, and treatment in healthcare by providing medical-grade wearables and software. Empatica’s flagship products, Embrace2 and E4, are designed to track physiological signals such as Heart Rate Variability, electrodermal activity, acceleration and movement, and skin temperature. These wearables are particularly noted for their application in epilepsy monitoring and seizure alerting.
Notable affiliated individuals include co-founder and CEO Matteo Lai. Empatica has received significant investment from prominent venture capital firms and has achieved FDA approval for its wearables. The company’s key achievements include the development of a comprehensive health monitoring platform and the receipt of new FDA clearance for cardiac digital biomarkers. Empatica’s impact is evidenced by its contributions to clinical trials and its role in setting new standards for physiological data interpretation in healthcare.
Companies similar to Empatica include Bios Health, Embr Labs, EMOTIV and DaVinci Wearables.
Empatica was founded in 2011.
Empatica's headquarters is located in Cambridge, MA, US.
Empatica's most recent funding round was for $25.9M (USD) in August 2022.
As of Aug 2, 2022, Empatica has raised a total of $33.7M (USD).
Empatica has 149 employees as of Feb 4, 2024.
EMOTIV
emotiv.com